HACKENSACK, N.J. and PETACH TIKVAH, Israel, Sept. 2, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chief Executive Officer Tony Fiorino, MD, PhD, will present a corporate update at the Rodman & Renshaw 17th Annual Global Investment Conference sponsored by H.C. Wainwright & Co. taking place September 8-10, 2015 at The St. Regis Hotel in New York, NY. Presentation and webcast details are as follows:
Rodman & Renshaw 17th Annual Global Investment Conference
Date: Thursday, September 10, 2015
Time: 10:00-10:25 AM ET
Location: St. Regis Hotel, New York, NY
Room: Library (2nd Floor)
The webcast may be accessed through the above link during the presentation and for 90 day afterwards.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 50 patients with ALS in clinical trials conducted in Israel and the United States, including the current randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company's website at www.brainstorm-cell.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-present-at-rodman--renshaw-17th-annual-global-investment-conference-300136705.html
SOURCE BrainStorm Cell Therapeutics Inc.